Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Pooled result · TIR 70-180 mg/dLResult — go to the resultMD 18.43 % 95% CI 12.40–24.46Authors' conclusion
In individuals with type 2 diabetes, AID is associated with short-term improvements in glycemic control, although the certainty of evidence is low to moderate.
Study context
- Population
- Adults with T2D in RCTs reporting 24-h TIR 70–180 mg/dL; databases searched until July 1, 2025
- Participants
- 714 adults9 studies
- Comparison
- Automated insulin delivery (AID) vs other glucose-lowering treatments
- Outcome
- 24-h TIR 70-180 mg/dL
Methodological detailsRoB2 risk of bias assessment
- RoB2 risk of bias assessment
Pooled result
TIR 70-180 mg/dL
MD
18.43 %
95% CI 12.40–24.46
AIDvs Controls
MD 18.43 % (95% CI 12.40–24.46)
As reported in the abstract
Further pooled results
Time above range (TAR), TAR >250 mg/dL, mean glucose, SD, HbA1c
- Improved with AID vs controls (TAR low certainty; SD and HbA1c moderate certainty)
Time below range (TBR), TBR <54 mg/dL, CV
- No differences between AID and controls (TBR moderate certainty)
Total daily insulin dose
- Similar total daily insulin doses
Safety
| Outcome | MD (kg) (95% CI) | |
|---|---|---|
| Body weightModest weight gain with AID | 1.58 (0.75–2.40) | |
| −10123Difference, kg (linear scale) |
Severe adverse events and DKA
- Episodes of DKA
- 0
- Severe adverse events, including severe hypoglycaemia, were rare
Original publication
Efficacy and Safety of Automated Insulin Delivery in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 27 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →